Hematologic Malignancy
Myelodysplastic/Myeloproliferative Neoplasm
CI-CAN-00001250Explore in graph →
Hematologic115 active trials3 approved drugs6 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00001250Explore in graph →
Clinical trials
528 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (77)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00708721 | Low-dose Oral Clofarabine for the Treatment of IPSS INT-1, INT-2 or HIGH Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia | terminated | Phase 1 / Phase 2 | 11 | University of UtahOTHER | 1 | Jun 1, 2017 | clinicaltrials |
| NCT00513474 | Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell Transplant | completed | Phase 1 | 46 | Massachusetts General HospitalOTHER | 1 | May 25, 2017 |
| clinicaltrials |
| NCT00555048 | Alemtuzumab, Busulfan, and Cyclophosphamide Followed By a Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer | terminated | Phase 1 / Phase 2 | 1 | Fred Hutchinson Cancer CenterOTHER | 1 | May 24, 2017 | clinicaltrials |
| NCT02564536 | Pacritinib in Combination With Low Dose Decitabine in Intermediate-High Risk Myelofibrosis or Myeloproliferative Neoplasm (MPN)/Myelodysplastic Syndrome (MDS) | withdrawn | Phase 1 | 0 | Washington University School of MedicineOTHER | 0 | May 8, 2017 | clinicaltrials |
| NCT00052520 | Biological Therapy in Treating Patients With Advanced Myelodysplastic Syndrome, Acute or Chronic Myeloid Leukemia, or Acute Lymphoblastic Leukemia Who Are Undergoing Stem Cell Transplantation | completed | Phase 1 / Phase 2 | 37 | Fred Hutchinson Cancer CenterOTHER | 1 | Mar 29, 2017 | clinicaltrials |
| NCT00104975 | Alemtuzumab and Combination Chemotherapy Followed By Donor Lymphocytes in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer | completed | Phase 1 | 20 | Yale UniversityOTHER | 1 | Dec 15, 2016 | clinicaltrials |
| NCT01398462 | Phase I Clinical Study of CWP232291 in Acute Myeloid Leukemia Patients | completed | Phase 1 | 69 | JW PharmaceuticalINDUSTRY | 2 | Mar 8, 2016 | clinicaltrials |
| NCT00664677 | Phase 1 Study of Terameprocol (EM-1421) in Patients With Leukemia | terminated | Phase 1 | 16 | Erimos PharmaceuticalsINDUSTRY | 1 | Feb 23, 2016 | clinicaltrials |
| NCT00014495 | Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Advanced Myeloid Cancer | completed | Phase 1 / Phase 2 | 32 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jan 22, 2016 | clinicaltrials |
| NCT01908387 | Phase 1 Study of CC-486 in Japanese Subjects With Hematological Neoplasms | terminated | Phase 1 | 2 | Celgene CorporationINDUSTRY | 1 | Jul 28, 2015 | clinicaltrials |
| NCT00800150 | Total Marrow and Total Lymph Node Irradiation, Fludarabine, and Melphalan Followed By Donor Stem Cell Transplant in Treating Patients With Advanced Hematological Cancer That Has Not Responded to Treatment | terminated | Phase 1 | 6 | City of Hope Medical CenterOTHER | 1 | Jun 8, 2015 | clinicaltrials |
| NCT00019656 | Perifosine in Treating Patients With Refractory Solid Tumors or Hematologic Cancer | completed | Phase 1 | — | National Cancer Institute (NCI)NIH | 1 | Apr 29, 2015 | clinicaltrials |
| NCT00669890 | Allogenic Stem Cell Transplantation in Patients With High Risk CD33+ AML/MDS/JMML(High Risk) | terminated | Phase 1 | 12 | New York Medical CollegeOTHER | 1 | Apr 22, 2015 | clinicaltrials |
| NCT01368757 | Lenalidomide in Patients With Chronic Myelomonocytic Leukemia | unknown | Phase 1 / Phase 2 | 30 | Arbeitsgemeinschaft medikamentoese TumortherapieOTHER | 1 | Mar 9, 2015 | clinicaltrials |
| NCT00351975 | Belinostat and Azacitidine in Treating Patients With Advanced Hematologic Cancers or Other Diseases | completed | Phase 1 | 56 | National Cancer Institute (NCI)NIH | 3 | Dec 23, 2014 | clinicaltrials |
| NCT00283114 | A Safety Study of Lintuzumab in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome | completed | Phase 1 | 82 | Seagen Inc.INDUSTRY | 1 | Dec 18, 2014 | clinicaltrials |
| NCT01164163 | INCB18424 in Treating Young Patients With Relapsed or Refractory Solid Tumor, Leukemia, or Myeloproliferative Disease | completed | Phase 1 | 49 | Children's Oncology GroupNETWORK | 1 | Oct 23, 2014 | clinicaltrials |
| NCT00217412 | Vorinostat With or Without Isotretinoin in Treating Young Patients With Recurrent or Refractory Solid Tumors, Lymphoma, or Leukemia | completed | Phase 1 | 60 | National Cancer Institute (NCI)NIH | 1 | Jun 17, 2014 | clinicaltrials |
| NCT00096122 | Idarubicin, Cytarabine, and Tipifarnib in Treating Patients With Newly Diagnosed Myelodysplastic Syndromes or Acute Myeloid Leukemia | completed | Phase 1 / Phase 2 | 95 | National Cancer Institute (NCI)NIH | 1 | May 26, 2014 | clinicaltrials |
| NCT01231919 | MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia | completed | Phase 1 | 45 | National Cancer Institute (NCI)NIH | 2 | Apr 29, 2014 | clinicaltrials |
| NCT00890747 | Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy | completed | Phase 1 | 42 | National Cancer Institute (NCI)NIH | 1 | Mar 17, 2014 | clinicaltrials |
| NCT00005845 | Tipifarnib in Treating Patients With Myelodysplastic Syndromes | completed | Phase 1 | 65 | National Cancer Institute (NCI)NIH | 1 | Dec 16, 2013 | clinicaltrials |
| NCT00049582 | Decitabine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia | terminated | Phase 1 | 36 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2013 | clinicaltrials |
| NCT00098423 | Tanespimycin and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, Chronic Myelomonocytic Leukemia, or Myelodysplastic Syndromes | completed | Phase 1 | 42 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2013 | clinicaltrials |
| NCT00301938 | 7-Hydroxystaurosporine and Perifosine in Treating Patients With Relapsed or Refractory Acute Leukemia, Chronic Myelogenous Leukemia or High Risk Myelodysplastic Syndromes | completed | Phase 1 | 30 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2013 | clinicaltrials |
| NCT00331513 | Vorinostat and Idarubicin in Treating Patients With Relapsed or Refractory Leukemia or Myelodysplastic Syndromes | completed | Phase 1 | 40 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2013 | clinicaltrials |
| NCT00049686 | VNP40101M in Treating Patients With Relapsed or Refractory Leukemia or Myelodysplastic Syndrome | completed | Phase 1 | — | Vion PharmaceuticalsINDUSTRY | 1 | Jul 18, 2013 | clinicaltrials |
| NCT00064090 | 3-AP and Cytarabine in Treating Patients With Hematologic Cancer | completed | Phase 1 | — | Vion PharmaceuticalsINDUSTRY | 1 | Jul 18, 2013 | clinicaltrials |
| NCT00697671 | Pilot Study of Haploidentical Natural Killer Cell Infusions for Poor Prognosis Non-AML Hematologic Malignancies | completed | Phase 1 | 48 | St. Jude Children's Research HospitalOTHER | 1 | Jul 16, 2013 | clinicaltrials |
| NCT00006040 | Radiolabeled Monoclonal Antibody Therapy and Etoposide Followed by Peripheral Stem Cell Transplantation in Treating Patients With Advanced Myelodysplastic Syndrome or Refractory Leukemia | completed | Phase 1 | — | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 19, 2013 | clinicaltrials |
| NCT00022048 | Bevacizumab in Treating Patients With Myelodysplastic Syndrome | completed | Phase 1 / Phase 2 | — | Stanford UniversityOTHER | 1 | May 15, 2013 | clinicaltrials |
| NCT00357305 | Vorinostat, Cytarabine, and Etoposide in Treating Patients With Relapsed and/or Refractory Acute Leukemia or Myelodysplastic Syndromes or Myeloproliferative Disorders | completed | Phase 1 | 25 | National Cancer Institute (NCI)NIH | 1 | May 3, 2013 | clinicaltrials |
| NCT00038051 | Evaluation of the Anti-CD-33 Immunotoxin Hum-195/rGel in Patients With Advanced Myeloid Malignancies | completed | Phase 1 | 28 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 4, 2013 | clinicaltrials |
| NCT00060372 | Ipilimumab After Allogeneic Stem Cell Transplant in Treating Patients With Persistent or Progressive Cancer | completed | Phase 1 | 21 | National Cancer Institute (NCI)NIH | 1 | Mar 27, 2013 | clinicaltrials |
| NCT00823524 | Donor Natural Killer Cells After Donor Stem Cell Transplant in Treating Patients With Advanced Cancer | completed | Phase 1 / Phase 2 | 47 | Asan Medical CenterOTHER | 1 | Feb 20, 2013 | clinicaltrials |
| NCT01101412 | Antimicrobial Solution or Saline Solution in Maintaining Catheter Patency and Preventing Catheter-Related Blood Infections in Patients With Malignancies | withdrawn | Phase 1 / Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Feb 15, 2013 | clinicaltrials |
| NCT00114257 | Decitabine and FR901228 in Treating Patients With Relapsed or Refractory Leukemia, Myelodysplastic Syndromes, or Myeloproliferative Disorders | completed | Phase 1 | 36 | National Cancer Institute (NCI)NIH | 1 | Feb 11, 2013 | clinicaltrials |
| NCT00095797 | XK469R in Treating Patients With Refractory Hematologic Cancer | completed | Phase 1 | 60 | National Cancer Institute (NCI)NIH | 1 | Feb 8, 2013 | clinicaltrials |
| NCT00025415 | Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction | completed | Phase 1 | 60 | National Cancer Institute (NCI)NIH | 1 | Feb 7, 2013 | clinicaltrials |
| NCT00005942 | Liposomal Daunorubicin and SU5416 in Treating Patients With Hematologic Cancer That Has Not Responded to Initial Therapy | completed | Phase 1 / Phase 2 | 37 | National Cancer Institute (NCI)NIH | 1 | Jan 23, 2013 | clinicaltrials |
| NCT00087204 | Rebeccamycin Analog in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemia | completed | Phase 1 | 40 | National Cancer Institute (NCI)NIH | 1 | Jan 23, 2013 | clinicaltrials |
| NCT00004245 | Sodium Salicylate in Treating Patients With Advanced Myelodysplastic Syndrome, Acute Myelogenous Leukemia, or Chronic Lymphocytic Leukemia | completed | Phase 1 | — | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jan 18, 2013 | clinicaltrials |
| NCT00012376 | Chemotherapy Plus Sargramostim in Treating Patients With Refractory Myeloid Cancer | completed | Phase 1 | 35 | National Cancer Institute (NCI)NIH | 1 | Jan 9, 2013 | clinicaltrials |
| NCT00357708 | Vorinostat and Decitabine in Treating Patients With Relapsed, Refractory, or Poor-Prognosis Hematologic Cancer or Other Diseases | completed | Phase 1 | 50 | National Cancer Institute (NCI)NIH | 1 | Jan 7, 2013 | clinicaltrials |
| NCT00006225 | Peripheral Stem Cell Transplantation in Treating Patients With Breast Cancer or Hematologic Cancer | completed | Phase 1 / Phase 2 | — | Northwestern UniversityOTHER | 1 | Jun 6, 2012 | clinicaltrials |
| NCT00719836 | A Phase 1/2 Study of SB1518 for the Treatment of Advanced Myeloid Malignancies | completed | Phase 1 / Phase 2 | 76 | S*BIOINDUSTRY | 1 | Apr 20, 2012 | clinicaltrials |
| NCT00064311 | Ravuconazole in Preventing Fungal Infections in Patients Undergoing Allogeneic Stem Cell Transplantation | completed | Phase 1 / Phase 2 | — | National Institutes of Health Clinical Center (CC)NIH | 1 | Mar 8, 2012 | clinicaltrials |
| NCT00080925 | T-Cell-Depleted Allogeneic Stem Cell Transplantation After Immunoablative Induction Chemotherapy and Reduced-Intensity Transplantation Conditioning in Treating Patients With Hematologic Malignancies | completed | Phase 1 | 20 | National Institutes of Health Clinical Center (CC)NIH | 1 | Mar 8, 2012 | clinicaltrials |
| NCT00074750 | Study of DT388GMCSF Fusion Protein in Acute Myelogenous Leukemia (AML) and Chronic Myelomonocytic Leukemia (CMML) | terminated | Phase 1 | 7 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 22, 2012 | clinicaltrials |
| NCT00093366 | Arsenic Trioxide and Etanercept in Treating Patients With Myelodysplastic Syndromes | completed | Phase 1 / Phase 2 | 32 | Fred Hutchinson Cancer CenterOTHER | 1 | Nov 30, 2011 | clinicaltrials |
Data updated 22 days agoSource updated Jun 1, 2017source: clinicaltrials